MRI Targeted Focal Laser Thermal Therapy of Biopsy Confirmed Prostate Cancer - Full Text View

Sponsored by:	University Health Network, Toronto
Information provided by:	University Health Network, Toronto
ClinicalTrials.gov Identifier:	NCT00448695

Purpose

The objective of this study is to establish the safety of MRI targeted laser thermal treatment for men with biopsy confirmed early stage low grade single sector prostate cancer.

Condition	Intervention	Phase
Prostate Cancer	Procedure: MRI Targeted Focal Thermal Therapy of Prostate Cancer	Phase I

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Phase 1 Study of MRI Targeted Focal Laser Thermal Therapy of Biopsy Confirmed Prostate Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Prostate Cancer

U.S. FDA Resources

Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:

Clinical assessment of: urinary, rectal, erectile function
validated self assessment tools of urinary, rectal, erectile function.

Secondary Outcome Measures:

Lesion size measured with 7-day MRI
6 month prostate biopsy

Estimated Enrollment:	12
Study Start Date:	March 2007

Detailed Description:

This is a single center, single arm, open-label Phase I study to establish the safety of interstitial laser thermal therapy (ILTT) in patients with a single site of low grade (Gleason <7) prostate cancer who have not yet received treatment for their cancer. No control group will be utilized and all patients will receive laser thermal therapy. The patient will undergo multimode MRI to determine if a single site of prostate cancer can be localized by this technique and to localize the tumor in 3 dimensions within the prostate. A multicore (12 + cores) mapping transrectal ultrasound guided biopsy of the prostate would then confirm that no other sites of cancer exist.

Each patient will complete quality of life and performance questionnaires. ILLT will be performed under general anesthetic in a procedure similar to brachytherapy, using transrectal ultrasound to guide insertion of the laser and monitoring probes into the sector containing the cancer as visualized by the MR scan. Following the procedure, patients will be assessed for clinical signs of urinary, rectal, and erectile complications and will complete validated self-assessment tools on these functions. MRI at 7 days and MRI and biopsy at 6 months will be used to assess the extent of tissue effect and presence of cancer due to ILTT. Patients will remain on standard Watchful Waiting surveillance for any further sign of disease progression. ILLT will not restrict any future treatment of prostate cancer.

To minimize the treatment risk, participants in the trial will be staged according to location of the disease in the prostate. The first 3 participants recruited to the trial will have targeted loci well separated from the urethra, erectile nerves and the rectum, and so treatment in this region poses minimal risk of injury to these vital structures. Lesions sizes measured in this initial stage will be used in planning fiber placement in the three remaining stages, in which fiber placement is closer to critical structures such as the urethra (Stage 2), erectile nerves (Stage 3) and rectum (Stage 4).

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Men > 18 years of age;
Histologically-proven prostate carcinoma;
Prostate cancer clinical stage T1c
Only one sector of the prostate demonstrating prostate cancer with no more than 1 core positive
Gleason score <7 ;
Each core must range between of 10 to 50% adenocarcinoma.
Prostate MRI must confirm area suspicious for cancer in the sector of the positive biopsy;
A minimum of six (6) weeks between the prostate biopsy and the Inclusion Visit;
Prostate specific antigen (PSA) level £ 10 ng/mL
PORPUS, IPSS, and IIEF complete prior to procedure
Prostate volume < 60 cc as measured by ultra sound;
Uroflow >12 cc/sec with post void residual < 100 cc.
Life expectancy of greater than 5 years, based on co-morbidity not related to prostate cancer.

Exclusion Criteria:Patients with any of the following exclusion criteria will be excluded from study participation:

Patients who are unwilling or unable to give informed consent;
Patients with foci location in the Apex of the prostate or isolated transition zone cancers
Patients who have received androgen suppression therapy
Patients who have received or are receiving chemotherapy for prostate carcinoma;
Patients previously treated with surgery to the prostate (traditional, endoscopic or minimally invasive including HIFU, TUNA, RITA, microwave, TURP ,cryotherapy or any curative treatment
Patients whose has undergone radiation therapy for prostate cancer
Any condition, or history of illness or surgery that, in the opinion of the Investigator , might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies);
Patients with a history of non compliance with medical therapy and/or medical recommendations;
Patients who are unwilling or unable to complete the patient self-assessment questionnaires;
Myocardial infarction, transient ischemic attack or stroke, within 6 months prior to the study, Unstable or uncontrolled angina, uncontrolled heart failure, or serious uncontrolled ventricular arrhythmias
Chronic or acute prostititis, neuroginic bladder, urinary tract infection, sphincter abnormalities, or any other symptom that prevents normal micturition.
Patients who have participated in a clinical study and/or received treatment with an investigational treatment and/or product within the past 90 days;
All medications that cause a decrease clotting, vasoconstriction or platelet aggregation, must be stopped prior to treatment.
History of Colon Cancer or Colon Surgery preformed
If the patient is unable to undergo anesthesia
Patients with contraindication to MRI (i.e. pacemaker, hip prosthesis, severe claustrophobia, brain aneurysm clip, allergy to MRI contrast agent).
Any condition, or history of illness that, in the opinion of the investigator will confound or increase the patient risk during the study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00448695

Contacts

Contact: Michael E Nesbitt, B.A.

416-946-4501 ext 6897

michael.nesbitt@uhn.on.ca

Locations

Canada, Ontario
Princess Margaret Hospital	Recruiting
Toronto, Ontario, Canada, M5G2M9
Principal Investigator: John Trachtenberg, M.D.

Sponsors and Collaborators

University Health Network, Toronto

Investigators

Principal Investigator:

John Trachtenberg, M.D.

University Health Network, Toronto

More Information

No publications provided

Study ID Numbers:	MRTA06-1
Study First Received:	March 16, 2007
Last Updated:	March 16, 2007
ClinicalTrials.gov Identifier:	NCT00448695 History of Changes
Health Authority:	Canada: Health Canada

Keywords provided by University Health Network, Toronto:

MRI
Laser Thermal Therapy
Focal Ablation
Prostate Cancer

Study placed in the following topic categories:

Prostatic Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Prostatic Diseases
Genital Neoplasms, Male

Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

ClinicalTrials.gov processed this record on September 02, 2009